Onco-TEK™ is a comprehensive solid tumor profiling assay that performs deep sequencing of a tumor's DNA and RNA to identify specific, actionable molecular signatures. From tumor classification and prognosis to targeted therapy selection and treatment personalization, Onco-TEK™ delivers the insights oncologists need to act with confidence.
When cancer has spread and requires a highly targeted approach.
When standard-of-care treatments have stopped working or the cancer has recurred.
Cases where traditional pathology does not provide a clear treatment path.
Patients seeking the latest investigational therapies.
Precision mapping provides data-driven guidance when standard treatment pathways are unclear.
Identifying Actionable Driver Mutations: Onco-TEK identifies the key genetic changes driving tumor growth, which can be matched to targeted therapies.
Determining Immunotherapy Eligibility: Markers such as MSI and TMB are measured to identify patients likely to benefit from immunotherapy.
Expanding Treatment Options: Tumor profiles are matched to relevant precision oncology clinical trials.
Informed Prognosis & Classification: Deep sequencing of tumor DNA and RNA enables accurate tumor classification and delivers the prognostic insights needed to guide next steps in care.
Single Nucleotide Variants (SNVs) and small Insertions/Deletions (indels).
Gene Copy Number Variations (CNVs)
Gene Fusions and Rearrangements
MSI (Microsatellite Instability): Determines eligibility for immunotherapy.
TMB (Tumor Mutational Burden): Measures total tumor mutations to predict immunotherapy response.
HRD (Homologous Recombination Deficiency): Identifies eligibility for targeted therapies like PARP inhibitors.
A simple, guided process from consultation to clinically actionable reporting.
Contact our team to learn how our tests can enhance your clinical offerings and improve patient outcomes.
Contact Sales Request Information